top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


The True Cost of a Poor Senior Hire in Life Sciences
A poor senior hire in Life Sciences can cost far more than recruitment fees and replacement expenses. Delayed milestones, lost productivity, weakened trust, and reduced willingness to speak up can all affect organizational performance. This article explores the financial and cultural impact—and how to reduce the risk before making a pivotal appointment.
sharonshieldsconsu
6 days ago4 min read


Q3 MedTech Earnings: Procedure-Driven Growth Meets Capital-Spending Pressure
Q3 2026 medtech results showed a widening gap between fast-growing innovators and companies facing pressure in key product lines. Abbott led among larger players, while Profound Medical and IRadimed posted strong growth from smaller bases. MiMedx and Dentsply Sirona struggled with revenue declines, highlighting how product mix and demand can shape performance across the sector.
sharonshieldsconsu
Nov 123 min read


Succession Planning in Life Sciences: Your Most Overlooked Risk Management Tool
Succession planning in the life sciences industry is not a “nice to have” HR process—it’s a core element of risk management and business continuity. Unplanned leadership gaps can delay clinical trials, regulatory submissions, manufacturing, and product launches, directly impacting patients and revenue. In this article, we explore when, why and how life sciences organisations should approach leadership succession, the mission‑critical roles to prioritise, and practical steps.
sharonshieldsconsu
Nov 73 min read


Redefining Neurodegeneration: From Plaques and Pathology to Systemic Network Dysfunction
From Single Targets to Systems Biology: A New Framework for Neurodegenerative R&D
For three decades, neurodegeneration programmes have been built around a tightly focused premise: find the toxic protein, clear it from the brain, protect the vulnerable neuron. Alzheimer’s was framed as an amyloid and tau problem. Parkinson’s as a dopamine and alpha-synuclein problem. ALS as a motor neuron problem.
That framing has driven real progress – from disease-modifying antibodies to g
sharonshieldsconsu
Sep 75 min read
bottom of page